Show simple item record

dc.rights.licenceAttribution-NonCommercial 4.0 International*
dc.contributor.authorBeracasa Caro, Lorena
dc.contributor.authorPardo Barón, Carlos Andrés
dc.contributor.authorSánchez, Jesús Oswaldo
dc.date.accessioned2021-05-26T14:26:15Z
dc.date.available2021-05-26T14:26:15Z
dc.date.created2021
dc.identifierhttps://revistas.javeriana.edu.co/index.php/vnimedica/article/view/30777/25041spa
dc.identifier.issn0041-9095 / 2011-0839 (Electrónico)spa
dc.identifier.urihttp://hdl.handle.net/10554/53895
dc.description.abstractLas patologías de origen tumoral son más frecuentes en la población adulta mayor; no obstante, el que dicha población tenga menos oportunidades de acceder a estudios diagnósticos e intervenciones terapéuticas impacta en la respuesta clínica a las distintas terapias que existen para tratar el cáncer, sumado al riesgo de toxicidad con la quimioterapia tradicional o con los esquemas de la inmunoterapia o terapia dirigida, que pueden generar toxicidad en menor grado, principalmente cardiovascular, hematológica, gastrointestinal y de piel. Teniendo en cuenta lo anterior se ha intentado avanzar en la predicción del riesgo de toxicidad a la quimiorradioterapia con diferentes modelos basados en cálculos clínicos y paraclínicos, muchos de los cuales se desprenden de la valoración geriátrica. Sin embargo, de manera global, estas herramientas de predicción del riesgo de toxicidad tienen varias limitaciones, como la falta de precisión al calcular el riesgo de toxicidad grave asociada a la quimiorradioterapia y muchas no están validadas, por lo que muchos estudios concluyen que se necesitan modelos más precisos a la hora de predecir dicho riesgo. No obstante, se ha evidenciado que combinar varias herramientas (funcionales y clínicas) mejora los resultados al modificar el plan de atención del paciente adulto mayor con cáncer.spa
dc.formatPDFspa
dc.format.mimetypeapplication/pdfspa
dc.language.isospaspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectAdulto mayorspa
dc.subjectCáncerspa
dc.subjectQuimioterapiaspa
dc.subjectToxicidadspa
dc.titleToxicidad relacionada con el tratamiento para el cáncer en adultos mayores. Revisión de la literaturaspa
dc.type.hasversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.identifier.doihttps://doi.org/10.11144/Javeriana.umed62-1.toxispa
dc.subject.keywordElderlyspa
dc.subject.keywordCancerspa
dc.subject.keywordChemotherapyspa
dc.subject.keywordToxicityspa
dc.description.abstractenglishPathologies of tumor origin are more frequent in the older adult population, however said population has fewer opportunities to access diagnostic studies and therapeutic interventions, not only due to the age and stage of the cancer, but also because they have conditions of aging such as decreased functional reserve, multiple pathologies, cognitive disorders, or lack of social support that impact on the clinical response to the different therapies that exist to treat cancer. In addition to this, the risk of toxicity conferred by the various cancer treatments, which leads to a more careful evaluation of the type of therapy, the dose, and the benefit of starting it. With the discovery of new therapies for cancer management, we not only face the risk of toxicity with traditional chemotherapy, but also the schemes developed in recent times, such as immunotherapy or targeted therapy, which can mainly generate toxicity to a lesser degree. cardiovascular, gastrointestinal and skin hematological. Taking into account the above, an attempt has been made to advance in the prediction of the risk of toxicity to chemo-radiotherapy, counting to date with different models based on clinical and paraclinical calculations, many of these criteria that come out of these tools are derived from the assessment geriatric (GV), we find tools to evaluate functional performance, cognitive status, social support, which provides valuable and comprehensive information for decision-making not only therapeutic, as well as models that include clinical and paraclinical parameters such as the CRASH tool which predicts non-hematological and joint hematological toxicity and the CARG tool that predicts joint toxicity. However, globally, these toxicity risk prediction tools have several limitations, such as the lack of precision when calculating the risk of severe toxicity associated with chemo-radiotherapy, many are not validated, so many studies conclude that models are needed more accurate when predicting such risk. However, it has been shown that combining various tools (functional and clinical) improves results on many occasions by modifying the care plan for the elderly patient with cancer.spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.type.localArtículosspa
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Instituto de Envejecimiento
dc.identifier.instnameinstname:Pontificia Universidad Javerianaspa
dc.identifier.reponamereponame:Repositorio Institucional - Pontificia Universidad Javerianaspa
dc.identifier.repourlrepourl:https://repository.javeriana.edu.cospa
dc.type.coarhttp://purl.org/coar/resource_type/c_6501spa
dc.relation.citationstartpage1spa
dc.relation.citationendpage18spa
dc.relation.ispartofjournalUniversitas Medicaspa
dc.description.indexingRevista Nacional - Indexadaspa
dc.relation.citationvolume62spa
dc.relation.citationissue1spa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International